Mass Spectrometric Detection and Reductive Degradation of the Anti-cancer Drugs Ifosfamide and Cyclophosphamide

C. Laauser¹, G. Habekost² and A. Habekost^1,

¹Ludwigsburg University of Education, Department of Chemistry, Reuteallee 46, D-71634 Ludwigsburg, Germany

²University of Hildesheim, Hildesheim, Germany

Cite this paper:
C. Laauser, G. Habekost and A. Habekost. Mass Spectrometric Detection and Reductive Degradation of the Anti-cancer Drugs Ifosfamide and Cyclophosphamide. Applied Ecology and Environmental Sciences. 2018; 6(1):15-22. doi: 10.12691/aees-6-1-3

Abstract

A flow tube reactor containing iron or zinc powder in a nitrogen atmosphere is capable of performing >90% anaerobic reductive dehalogenation of the cancer drugs ifosfamide and cyclophosphamide at 400 °C using toluene, alcohol or water as proton donors and iron or zinc as reducing agents. The products are all chlorine-free, as proven by GC-MS. The process is particularly interesting for large-scale industrial applications.

Keywords:
reductive dehalogenation anti-cancer drugs mass spectrometry

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	https://ptaforum.pharmazeutische-zeitung.de/index.php?id=5977.
[2]	S. Frustaci, S. Foladore, A. Buonadonna, A. De Paoli, D. Crivellari, A. Carbone, R. Sorio, S. Morassut, Epirubicin and ifosfamide in advanced soft tissue sarcomas, Ann Oncol. 4, 669-72, 1993.
[3]	M. Mohrmann, S. Ansorge, U. Schmich, B. Schönfeld, M. Brandis, Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture, Pediatr Nephrol. 8, 157-163, 1994.
[4]	http://onlinelibrary.wiley.com/doi/10.1002/3527600418.mb10702e0016/pdf.
[5]	N. Brock, J. Pohl, J. Stekar, Studies on the Urotoxicity of Oxazaphosphorine Cytostatics and its Prevention. 2. Comparative studiy on the Uorprotective Efficacy of Thiols and other Sulfur Compounds, Eur. J. Cancer Clin. Oncol. 17, 1155-1163, 1981.
[6]	S. MacAllister, N. Martin-Brisac, V. Lau, K. Yang, P.J. O’Brien, Acrolein and chloroacetaldehyde: An examination of the cell and cell-free biomarkers of toxicity, Chemico-Biological Interactions 202, 259-266, 2013.
[7]	J. Zhang, V.W.C. Chang, A. Giannis, J-Y. Wang, Removal of cyctostatic drugs from aquatic environment: A review, Science of the Total Environment, 445-446, 281-298, 2013.
[8]	M. Cesen, T. Kosjek, M. Laimou-Geraniou, B. Kompare, B. Sirok, D. Lambropolou, E. Heath, Occurrence of cyclophosphamide and ifosfamide in aqueous environment and their removal by biological and abiotic wastewater, Science of the Total Environment, 527-528, 465-473, 2015.
[9]	C.A. Lutterbeck, E.L. Machado, K. Kümmerer, Photodegradation of the antineoplastic cyclophosphamide: A comparative study of the efficiencies of UV/H2O2, UV/Fe2+/H2O2 or UV/TiO2 processes, Chemosphere, 120, 538-546, 2015.
[10]	C.A. Lutterbeck, M.L. Wilde, E. Baginska, C. Leder, E.L. Machado, K. Kümmerer, Degradation of cyclophosphamide and 5-fluorouracil by UV and simulated sunlight treatments: Assessment of the enhancement of the biodegradability and toxicity, Environm. Poll. 208, 467-476, 2016.
[11]	H.H-H. Lin, A. Y-C. Lin, Photocatalytic oxidation of 5-fluorouracil and cyclophosphamide via UV/TiO2 in an aqueous environment, Wat. Res. 48, 559-568, 2014.
[12]	A. Paci, T. Martens, J. Royer, Anodic Oxidation of Ifosfamide and Cyclophosphamide: A Biomimetic Metabolism Model of the Oxazaphosphorinane Anticancer Drugs, Bioorganic & Medicinal Chem. Lett. 11, 1347-1349, 2001.
[13]	A. Fabianska, A. Ofiarska, A. Fiszka-Borzyszkowska, P. Stepnowski, E.M. Siedlecka, Electrodegradation of ifosfamide and cyclophosphamide at BDD electrode: Decomposition pathway and its kinetics, Chem. Engin. Journal 276, 274-282, 2015.
[14]	B.B. Prasad, A. Kumar, R. Singh, Synthesis of novel monomeric graphene quantum dots and corresponding nanocomposite with molecularly imprinted polymer for electrochemical detection of an anticancerous ifosfamide drug, Biosensors and Bioelectronics 94, 1-9, 2017.
[15]	N. Aristov, A. Habekost, Heterogeneous dehalogenation of PCBs with iron/toluene or iron/quicklime, Chemosphere, 80, 113-115, 2010.
[16]	A. Habekost, N. Aristov, Heterogeneous reductive dehalogenation of PCB contaminated transformer oil and brominated diphenyl ethers with zero valent iron, Chemosphere, 88, 1283-1287, 2012.